S&P 500   3,351.60 (+1.61%)
DOW   27,584.06 (+1.51%)
QQQ   276.59 (+1.85%)
AAPL   114.71 (+2.16%)
MSFT   209.25 (+0.69%)
FB   256.85 (+0.80%)
GOOGL   1,458.00 (+1.32%)
AMZN   3,169.98 (+2.42%)
TSLA   421.67 (+3.52%)
NVDA   519.23 (+0.83%)
BABA   275.71 (+1.70%)
CGC   14.20 (+0.21%)
GE   6.21 (+1.64%)
MU   49.59 (+0.92%)
AMD   79.26 (+1.54%)
T   28.38 (+1.21%)
F   6.71 (+3.07%)
ACB   4.78 (-5.35%)
GILD   62.75 (+0.80%)
NFLX   489.93 (+1.46%)
DIS   125.94 (+1.56%)
BA   166.03 (+6.41%)
BAC   24.08 (+2.51%)
S&P 500   3,351.60 (+1.61%)
DOW   27,584.06 (+1.51%)
QQQ   276.59 (+1.85%)
AAPL   114.71 (+2.16%)
MSFT   209.25 (+0.69%)
FB   256.85 (+0.80%)
GOOGL   1,458.00 (+1.32%)
AMZN   3,169.98 (+2.42%)
TSLA   421.67 (+3.52%)
NVDA   519.23 (+0.83%)
BABA   275.71 (+1.70%)
CGC   14.20 (+0.21%)
GE   6.21 (+1.64%)
MU   49.59 (+0.92%)
AMD   79.26 (+1.54%)
T   28.38 (+1.21%)
F   6.71 (+3.07%)
ACB   4.78 (-5.35%)
GILD   62.75 (+0.80%)
NFLX   489.93 (+1.46%)
DIS   125.94 (+1.56%)
BA   166.03 (+6.41%)
BAC   24.08 (+2.51%)
S&P 500   3,351.60 (+1.61%)
DOW   27,584.06 (+1.51%)
QQQ   276.59 (+1.85%)
AAPL   114.71 (+2.16%)
MSFT   209.25 (+0.69%)
FB   256.85 (+0.80%)
GOOGL   1,458.00 (+1.32%)
AMZN   3,169.98 (+2.42%)
TSLA   421.67 (+3.52%)
NVDA   519.23 (+0.83%)
BABA   275.71 (+1.70%)
CGC   14.20 (+0.21%)
GE   6.21 (+1.64%)
MU   49.59 (+0.92%)
AMD   79.26 (+1.54%)
T   28.38 (+1.21%)
F   6.71 (+3.07%)
ACB   4.78 (-5.35%)
GILD   62.75 (+0.80%)
NFLX   489.93 (+1.46%)
DIS   125.94 (+1.56%)
BA   166.03 (+6.41%)
BAC   24.08 (+2.51%)
S&P 500   3,351.60 (+1.61%)
DOW   27,584.06 (+1.51%)
QQQ   276.59 (+1.85%)
AAPL   114.71 (+2.16%)
MSFT   209.25 (+0.69%)
FB   256.85 (+0.80%)
GOOGL   1,458.00 (+1.32%)
AMZN   3,169.98 (+2.42%)
TSLA   421.67 (+3.52%)
NVDA   519.23 (+0.83%)
BABA   275.71 (+1.70%)
CGC   14.20 (+0.21%)
GE   6.21 (+1.64%)
MU   49.59 (+0.92%)
AMD   79.26 (+1.54%)
T   28.38 (+1.21%)
F   6.71 (+3.07%)
ACB   4.78 (-5.35%)
GILD   62.75 (+0.80%)
NFLX   489.93 (+1.46%)
DIS   125.94 (+1.56%)
BA   166.03 (+6.41%)
BAC   24.08 (+2.51%)
Log in
NASDAQ:BIOL

BIOLASE Stock Forecast, Price & News

$0.28
0.00 (-1.32 %)
(As of 09/28/2020 03:51 PM ET)
Add
Compare
Today's Range
$0.28
Now: $0.28
$0.29
50-Day Range
$0.27
MA: $0.34
$0.44
52-Week Range
$0.21
Now: $0.28
$1.07
Volume38,471 shs
Average Volume4.43 million shs
Market Capitalization$25.47 million
P/E RatioN/A
Dividend YieldN/A
Beta1.95
BIOLASE, Inc., a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company also markets, sells, and distributes dental imaging equipment comprising three-dimensional (3D) CAD/CAM intra-oral scanners and digital dentistry software. Its dental imaging products include 3Shape TRIOS intraoral scanners, digital impression systems, and software for taking 3D scans, which are used to design crowns, study models, surgical guides for implant placement, and event orthodontic and athletic appliances. In addition, the company manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. It sells its products primarily to dentists in general practice through its field sales force and distributor network. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.
Read More
BIOLASE logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.63 out of 5 stars


Industry, Sector and Symbol

Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BIOL
Previous SymbolNASDAQ:BLTI
CUSIPN/A
Phone949-361-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$37.80 million
Book Value$0.01 per share

Profitability

Net Income$-17,850,000.00

Miscellaneous

Employees190
Market Cap$25.47 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$0.28
0.00 (-1.32 %)
(As of 09/28/2020 03:51 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BIOL News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BIOLASE (NASDAQ:BIOL) Frequently Asked Questions

How has BIOLASE's stock price been impacted by Coronavirus?

BIOLASE's stock was trading at $0.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BIOL shares have decreased by 52.4% and is now trading at $0.2763.
View which stocks have been most impacted by COVID-19
.

When is BIOLASE's next earnings date?

BIOLASE is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for BIOLASE
.

How were BIOLASE's earnings last quarter?

BIOLASE Inc (NASDAQ:BIOL) issued its earnings results on Thursday, August, 13th. The medical technology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.05. The medical technology company earned $2.94 million during the quarter. BIOLASE had a negative return on equity of 645.85% and a negative net margin of 74.39%.
View BIOLASE's earnings history
.

When did BIOLASE's stock split? How did BIOLASE's stock split work?

Shares of BIOLASE reverse split before market open on Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.

Who are some of BIOLASE's key competitors?

What other stocks do shareholders of BIOLASE own?

Who are BIOLASE's key executives?

BIOLASE's management team includes the following people:
  • Mr. Todd A. Norbe, Pres, CEO & Director (Age 52)
  • Mr. John R. Beaver, Exec. VP & CFO (Age 58)
  • Mr. Richard R. Whipp, VP of Operations (Age 67)
  • Mr. William E. Brown Jr., VP of Bus. Devel. (Age 71)
  • Mr. Daniel Merkin, National Sales Director (Age 46)

What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

Who are BIOLASE's major shareholders?

BIOLASE's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Oracle Investment Management Inc. (3.45%) and Jane Street Group LLC (0.21%). Company insiders that own BIOLASE stock include Garrett Sato, Jack W Schuler, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe.
View institutional ownership trends for BIOLASE
.

Which institutional investors are selling BIOLASE stock?

BIOL stock was sold by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc.. Company insiders that have sold BIOLASE company stock in the last year include Jack W Schuler, and Larry N Feinberg.
View insider buying and selling activity for BIOLASE
.

Which institutional investors are buying BIOLASE stock?

BIOL stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC. Company insiders that have bought BIOLASE stock in the last two years include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg, and Todd Norbe.
View insider buying and selling activity for BIOLASE
.

How do I buy shares of BIOLASE?

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BIOLASE's stock price today?

One share of BIOL stock can currently be purchased for approximately $0.28.

How big of a company is BIOLASE?

BIOLASE has a market capitalization of $25.47 million and generates $37.80 million in revenue each year. The medical technology company earns $-17,850,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. BIOLASE employs 190 workers across the globe.

What is BIOLASE's official website?

The official website for BIOLASE is www.biolase.com.

How can I contact BIOLASE?

BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]

This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.